Epidemiology of prostate Cancer: comparative analysis of major urological cancers
DOI:
https://doi.org/10.48193/cpthsn35Keywords:
Cancer, prostate cancer, incidence, mortality, genitourinary tumorsAbstract
Cancer presents as a leading cause of mortality worldwide, with its incidence exhibiting an upward trend attributable to population aging, the implementation of novel diagnostic tools, and the availability of innovative therapies. In males, prostate cancer stands out as one of the neoplasms with the highest incidence and prevalence, further associated with an elevated mortality rate, excluding skin cancer. A detailed understanding of the incidence, mortality, and particularly, the disease burden of this neoplasm is of paramount relevance, as it allows for the formulation and implementation of measures and strategies in health policies aimed at mitigating the negative impact on both public health and national economies. Globally in 2021, 432,463 deaths due to prostate cancer were recorded, whereas in Mexico the figure reached 8,860. In Mexico and worldwide, prostate cancer is a highly prevalent neoplasm and represents a substantial disease burden. Timely intervention is necessary to mitigate its impact.
References
Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16): 3029–3030. https://doi.org/10.1002/cncr.33587.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon: International agency for research on cancer. 2020;20182020.
Bray F, Soerjomataram I. The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control. In: Gelband H, Jha P, Sankaranarayanan R, Horton S (eds.) Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2015. http://www.ncbi.nlm.nih.gov/books/NBK343643/
Tian YQ, Yang JC, Hu JJ, Ding R, Ye DW, Shang JW. Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the Global Burden of Disease Study 2019. Frontiers in Public Health. 2023;11: 1119374. https://doi.org/10.3389/fpubh.2023.1119374.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024;74(3): 229–263. https://doi.org/10.3322/caac.21834.
Zi H, He SH, Leng XY, Xu XF, Huang Q, Weng H, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019. Military Medical Research. 2021;8(1): 60. https://doi.org/10.1186/s40779-021-00354-z.
Su X, Tao Y, Chen F, Han X, Xue L. Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021. Scientific Reports. 2025;15(1): 7655. https://doi.org/10.1038/s41598-025-92033-5.
Cirillo L, Innocenti S, Becherucci F. Global epidemiology of kidney cancer. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2024;39(6): 920–928. https://doi.org/10.1093/ndt/gfae036.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70(1): 7–30. https://doi.org/10.3322/caac.21590.
World Health Organization. The Global Initiative for Childhood Cancer. World Health Organization. 2023. https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer
World Health Organization. SDG Target 3.4 | Noncommunicable diseases and mental health: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being. The Global Health Observatory.2024 https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.4-noncommunicable-diseases-and-mental-health
dos-Santos-Silva I, Gupta S, Orem J, Shulman LN. Global disparities in access to cancer care. Communications Medicine. 2022;2: 31. https://doi.org/10.1038/s43856-022-00097-5.
Mattiuzzi C, Lippi G. Current Cancer Epidemiology. Journal of Epidemiology and Global Health. 2019;9(4): 217–222. https://doi.org/10.2991/jegh.k.191008.001.
US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18): 1901–1913. https://doi.org/10.1001/jama.2018.3710.
American cancer Society (apellido). Key Statistics for Prostate Cancer. American cancer Society. 2025.
International Agency for Research on Cancer. Cancer Today. 2025. https://gco.iarc.who.int/today/
James ND, Tannock I, N’Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet (London, England). 2024;403(10437): 1683–1722. https://doi.org/10.1016/S0140-6736(24)00651-2.
Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA. 2015;314(19): 2054–2061. https://doi.org/10.1001/jama.2015.14905.
Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2012;157(2): 120–134. https://doi.org/10.7326/0003-4819-157-2-201207170-00459.
Borregales LD, DeMeo G, Gu X, Cheng E, Dudley V, Schaeffer EM, et al. Grade Migration of Prostate Cancer in the United States During the Last Decade. Journal of the National Cancer Institute. 2022;114(7): 1012–1019. https://doi.org/10.1093/jnci/djac066.
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review. European urology. 2023;84(2): 191–206. https://doi.org/10.1016/j.eururo.2023.04.021.
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. Journal of the National Cancer Institute. 2013;105(14): 1050–1058. https://doi.org/10.1093/jnci/djt151.
Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU international. 2003;91(9): 789–794. https://doi.org/10.1046/j.1464-410x.2003.04232.x
